In an effort to advance on groundbreaking solutions in distributed
technology, Shivom, a startup engaged in next era genomic advancements through
blockchain technology, recently announced a major partnership with leading
molecular diagnostics company Genetic Technologies
(GTG). It is hoped that this new development will accelerate the
prediction of cancer for millions of individuals worldwide.
which has built a clinically validated risk assessment test for nonhereditary
breast cancer, is at the forefront of preventive medicine. While the collection
of data to develop that test took over seven years to complete, the company’s
partnership with Shivom is expected to massively reduce such timelines.
Axel Schumacher, the co-founder and CEO of Shivom, said that this
with GTG is significant because bringing together millions of individual
genomic profiles will allow the critical mass needed to accelerate
transformative disease prevention and personalized healthcare.
sort of big data analysis and healthcare servicing is only possible through blockchain
[technology],” added Gourish Singla, co-founder and COO of Shivom, per a
release on the partnership. “The low-cost management of data that it enables allows us to
revolutionize how genomics is presented to the world.”
blockchain-centric healthcare platform, which endeavors to become the largest
unique genomic and healthcare data hub on the planet, puts ownership of genome
data into the hands of individuals. Via its innovative “Global Genome ID,”
Shivom aims to revolutionize preventative healthcare, including impacting how
cures to 7,000 rare genetic diseases are discovered.
partnership with GTG will allow Shivom to tap into the rich history of research
investment and transformative personalized healthcare services. By integrating
Shivom’s huge database of genomics data, GTG will be able to identify cancer
risks and other diseases much more quickly than was previously possible.
believe blockchain technology will open up markets to make it much more
efficient to catch many more users and many more practitioners,” said Dr. Paul
Kasian, chairman and interim CEO of GTG, according to a
press release. “Not only that, by
using the Shivom platform to its full potential, we will also be able to access
the benefits of research in collaboration with other personalized healthcare
cost-effective method of assessing the risk of nonhereditary breast cancer in
women (a cancer that 1 in every 11 women develops in their lifetime) underscores
the importance of the collaboration with Shivom — namely, that the volume of unique and ethnically diverse global
genomic data available via Shivom’s platform will greatly accelerate this
process for new testing.